Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Platinum-based chemotherapy and PARP inhibitors are two types of treatment that can benefit prostate cancer patients with mutations in genes that are involved in the repair of damage in the DNA. However, patients who receive one type of treatment may not respond as well to the other...

Descripción completa

Detalles Bibliográficos
Autores principales: Slootbeek, Peter H. J., Kloots, Iris S. H., van Oort, Inge M., Kroeze, Leonie I., Schalken, Jack A., Bloemendal, Haiko J., Mehra, Niven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216363/
https://www.ncbi.nlm.nih.gov/pubmed/37345149
http://dx.doi.org/10.3390/cancers15102814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216363/
https://www.ncbi.nlm.nih.gov/pubmed/37345149
http://dx.doi.org/10.3390/cancers15102814

Ejemplares similares